H.C. Wainwright lowered the firm’s price target on TC Biopharm (TCBP) to $3 from $7 and keeps a Buy rating on the shares. The firm updated its model to reflect launch timing, market trends, and capital structure changes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCBP: